POET Technologies (NASDAQ:POET) is a leading AI photonics story on the Nasdaq with real momentum heading into earnings. A fortress balance sheet, marquee Lumilens contract, and Malaysia production ramp moving from plans to shipments create an asymmetric risk/reward.
Our 24/7 Wall St. price target for POET is $21.14, implying 146.96% upside from $8.56. Our recommendation is buy at medium confidence.
24/7 Wall St. Price Target Summary
| Metric | Value |
|---|---|
| Current Price | $8.56 |
| 24/7 Wall St. Price Target | $21.14 |
| Upside | 146.96% |
| Recommendation | BUY |
| Confidence Level | 50% |
Stock Performance and Q1 2026 Results
POET shares are up 35.23% year to date and 55.92% over the past year, though trading 16% below the 52-week high of $20.81.
Q1 2026 revenue of $503,390 beat estimates by 44.66% and grew 201.9% year over year. The reported loss of $0.08 missed the $0.04 loss consensus as warrant gains normalized.
Recent catalysts cut both ways. A board refresh adding Dr. Bardia Pezeshki and Jean F. Rankin sent shares up 6.24% in early August. Lumilens closing a $700 million funding round validated POET’s largest customer relationship. Offsetting that: class action lawsuits tied to PFIC disclosures and the Celestial AI purchase order cancellation earlier this summer.
The Bull Case
POET expects to ship more than 30,000 optical engines in 2026, with high-volume 800G production beginning Q3 2026 at the Malaysia facility. The Lumilens agreement carries a $50 million initial purchase order with potential to exceed $500 million over five years. Management flagged 10+ active customer engagements projected to generate more than $100 million in future annual revenue.
The balance sheet is unusually strong for a company this size, with $815.7 million in pro forma liquidity. One analyst issued a Buy rating with a $20.25 price target. The bull case scenario points to $22.02 over 12 months.
What Could Go Wrong
The bear case starts with dilution. POET raised $830 million in equity this year, with another $661 million in potential warrant exercises pending. Litigation over PFIC status and the Celestial AI cancellation remain overhangs. A material weakness in internal controls disclosed in the 2024 audit adds risk.
Bulls counter that the redomicile to the U.S. structurally eliminates the PFIC issue, and capital raises enable the Malaysia ramp. The bear scenario still lands at $14.08, above today’s price.
How POET Compares to Peers
Lumentum (NASDAQ:LITE | LITE Price Prediction) is the direct benchmark on 800G/1.6T transceiver optics and generates profits, giving it a meaningful forward P/E where POET has none. That contrast makes POET’s price-to-sales ratio of 1089 look aggressive on today’s revenue base. Our $21.14 target is entirely a bet on the 2027 revenue ramp.
Coherent (NYSE:COHR) has a much larger optical portfolio and diversified end markets. Coherent’s scale highlights POET’s execution risk: hyperscalers prefer proven vendors. Against these peers, our $21.14 target looks reasonable if Malaysia hits volume, and aggressive if it slips a quarter.
POET Technologies Price Prediction 2026-2030
The $21.14 price target and buy rating at medium confidence reflect a real asymmetric setup.
The thesis strengthens if Q3 2026 confirms 800G volume production and Lumilens shipments hit schedule. It weakens if the August 14 report shows customer qualification slippage or a fresh dilutive raise beyond current warrants. The Lumilens contract tips the scale.
| Year | 24/7 Wall St. Price Target |
|---|---|
| 2026 | $11.74 |
| 2027 | $21.00 |
| 2028 | $39.57 |
| 2029 | $62.31 |
| 2030 | $86.20 |
These projections assume POET executes on its 1 million units per month capacity target by end of 2027 and converts its customer pipeline into recurring revenue. Significant downside could result from litigation, dilution, or Malaysia ramp delays.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks